- Hospitals are at risk of running low of drugs that are critical to the treatment of the novel coronavirus, according to new data from hospital supply company Premier.
- That includes medications like chloroquine and hydroxychloroquine, as well as sedatives used when patients are put on ventilators to help them breathe.
- The lack of drugs used while patients are on ventilators could ultimately limit the US’s response to the pandemic.
- Visit Business Insider’s homepage for more stories.
As hospitals around the US grapple with a rising number of coronavirus patients falling critically ill, the country has started running low on the drugs used to treat those patients.
Premier, which works with hospitals around the US in part by helping them purchase medications, on Tuesday pulled together a list of drugs at risk of shortages. Some of the treatments are officially in shortage, according to the US Food and Drug Administration. Others are seeing demand skyrocket, making it difficult for hospitals to get their orders filled.
“Any time you’re not seeing orders 100% fulfilled is when you start having an early warning sign that a shortage may be coming,” Soumi Saha, a senior director of advocacy at Premier, told Business Insider.
Never miss out on healthcare news. Subscribe to Dispensed, our weekly newsletter on pharma, biotech, and healthcare.
It also includes drugs used when putting patients on ventilators to help with their breathing, including sedatives like fentanyl, midazolam, and propofol and neuromuscular blockers cisatracurium and rocuronium, a survey conducted by Premier found.
That could pose a problem if drug manufacturers can’t respond to the surge in demand.
Patients using ventilators to help with breathing and give the lungs a chance to recover from the virus are typically sedated throughout the treatment to keep them from interfering with the breathing tube. While supplies of ventilators can be made by other manufacturers, standing up new drugmakers to help keep up with demand isn’t quite as simple.
“The biggest challenge with drugs is that it’s not resilient,” Saha said. “Drugs is where you have to be extremely proactive. You have to leverage early warning signals right now.”
Saha said the buying habits she’s seeing from hospitals are “unprecedented,” especially given how much of current treatment for the virus is still being determined.
For instance, purchases of ascorbic acid, otherwise known as Vitamin C, rose almost overnight after the publication of a study showing its positive effects in intensive care treatment for the novel coronavirus. That could pose a problem, as there’s only one manufacturer of ascorbic acid for hospital use in the US.
“Nobody wants to be in a situation where they don’t have drugs on hand,” Saha said.
Business Insider Emails & Alerts
Site highlights each day to your inbox.